{"id":38603,"date":"2025-08-05T13:53:28","date_gmt":"2025-08-05T05:53:28","guid":{"rendered":"https:\/\/flcube.com\/?p=38603"},"modified":"2025-08-05T13:53:29","modified_gmt":"2025-08-05T05:53:29","slug":"zhongheng-group-acquires-patent-for-innovative-chronic-heart-failure-drug-lz-01","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38603","title":{"rendered":"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01"},"content":{"rendered":"\n<p>China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600252:SHA\">SHA: 600252<\/a>) announced that its wholly-owned subsidiary, Zhongheng Innovation, has acquired the patent for LZ-01, a Class 1 innovative chemical drug for the treatment of chronic heart failure. The acquisition, valued at RMB 55 million, was completed through a public listing on the Shanghai Technology Exchange from China Rongtong Scientific Research Institute Group Co., Ltd. The &#8220;Technology (Patent Rights) Transfer Contract&#8221; was signed on August 1.<\/p>\n\n\n\n<p><strong>Acquisition Details<\/strong><br>Under the contract, Zhongheng Innovation will pay the transfer fee in phased milestone payments. Zhongheng Innovation will be responsible for the IND\/NDA submissions, clinical registration, and process validation. The original rights holder will assist with document preparation, technical handover, and regulatory review responses.<\/p>\n\n\n\n<p><strong>LZ-01 Development<\/strong><br>LZ-01, discovered by the Naval Medical University of the Chinese People&#8217;s Liberation Army, is a compound with a novel target. It has the potential to significantly improve cardiac function and myocardial remodeling in chronic heart failure. The drug is administered orally and currently has no similar products on the market in China or abroad. It is in the preclinical research stage and shows significant therapeutic advantages for chronic heart failure with reduced ejection fraction.<\/p>\n\n\n\n<p><strong>Mechanism and Innovation<\/strong><br>LZ-01 focuses on enhancing myocardial tissue energy metabolism, setting it apart from existing treatments that primarily inhibit the neuro-humoral system. This innovative mechanism is expected to address an unmet clinical need in the treatment of chronic heart failure.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600252_20250805_YC13.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600252_20250805_YC13.\"><\/object><a id=\"wp-block-file--media-fe89c42f-960b-4ce4-ba7f-d8be1456c8cd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600252_20250805_YC13.pdf\">600252_20250805_YC13<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600252_20250805_YC13.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fe89c42f-960b-4ce4-ba7f-d8be1456c8cd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38604,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[69,909,529],"class_list":["post-38603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cvd","tag-sha-600252","tag-zhongheng-group"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng Innovation, has acquired the patent for LZ-01, a Class 1 innovative chemical drug for the treatment of chronic heart failure. The acquisition, valued at RMB 55 million, was completed through a public listing on the Shanghai Technology Exchange from China Rongtong Scientific Research Institute Group Co., Ltd. The &quot;Technology (Patent Rights) Transfer Contract&quot; was signed on August 1.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38603\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01\" \/>\n<meta property=\"og:description\" content=\"China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng Innovation, has acquired the patent for LZ-01, a Class 1 innovative chemical drug for the treatment of chronic heart failure. The acquisition, valued at RMB 55 million, was completed through a public listing on the Shanghai Technology Exchange from China Rongtong Scientific Research Institute Group Co., Ltd. The &quot;Technology (Patent Rights) Transfer Contract&quot; was signed on August 1.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38603\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-05T05:53:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-05T05:53:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0506.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01\",\"datePublished\":\"2025-08-05T05:53:28+00:00\",\"dateModified\":\"2025-08-05T05:53:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0506.webp\",\"keywords\":[\"CVD\",\"SHA: 600252\",\"Zhongheng Group\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38603#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38603\",\"name\":\"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0506.webp\",\"datePublished\":\"2025-08-05T05:53:28+00:00\",\"dateModified\":\"2025-08-05T05:53:29+00:00\",\"description\":\"China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng Innovation, has acquired the patent for LZ-01, a Class 1 innovative chemical drug for the treatment of chronic heart failure. The acquisition, valued at RMB 55 million, was completed through a public listing on the Shanghai Technology Exchange from China Rongtong Scientific Research Institute Group Co., Ltd. The \\\"Technology (Patent Rights) Transfer Contract\\\" was signed on August 1.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38603\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0506.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0506.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38603#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01 - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng Innovation, has acquired the patent for LZ-01, a Class 1 innovative chemical drug for the treatment of chronic heart failure. The acquisition, valued at RMB 55 million, was completed through a public listing on the Shanghai Technology Exchange from China Rongtong Scientific Research Institute Group Co., Ltd. The \"Technology (Patent Rights) Transfer Contract\" was signed on August 1.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38603","og_locale":"en_US","og_type":"article","og_title":"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01","og_description":"China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng Innovation, has acquired the patent for LZ-01, a Class 1 innovative chemical drug for the treatment of chronic heart failure. The acquisition, valued at RMB 55 million, was completed through a public listing on the Shanghai Technology Exchange from China Rongtong Scientific Research Institute Group Co., Ltd. The \"Technology (Patent Rights) Transfer Contract\" was signed on August 1.","og_url":"https:\/\/flcube.com\/?p=38603","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-05T05:53:28+00:00","article_modified_time":"2025-08-05T05:53:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0506.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38603#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38603"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01","datePublished":"2025-08-05T05:53:28+00:00","dateModified":"2025-08-05T05:53:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38603"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38603#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0506.webp","keywords":["CVD","SHA: 600252","Zhongheng Group"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38603#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38603","url":"https:\/\/flcube.com\/?p=38603","name":"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38603#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38603#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0506.webp","datePublished":"2025-08-05T05:53:28+00:00","dateModified":"2025-08-05T05:53:29+00:00","description":"China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng Innovation, has acquired the patent for LZ-01, a Class 1 innovative chemical drug for the treatment of chronic heart failure. The acquisition, valued at RMB 55 million, was completed through a public listing on the Shanghai Technology Exchange from China Rongtong Scientific Research Institute Group Co., Ltd. The \"Technology (Patent Rights) Transfer Contract\" was signed on August 1.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38603#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38603"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38603#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0506.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0506.webp","width":1080,"height":608,"caption":"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38603#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0506.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38603"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38603\/revisions"}],"predecessor-version":[{"id":38606,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38603\/revisions\/38606"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38604"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}